CClinicalTrials.gg
Not yet recruitingNCT06246539Updated Aug 17, 2026

Impact of a Virtual Reality-based Mindfulness Program on Clinician Wellness

An interventional study of VR mindfulness in Wellness, Psychological, sponsored by University of Massachusetts, Worcester. Not yet recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by University of Massachusetts, Worcester · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Sex
All
01

Study summary

Burnout shares symptoms with anxiety and depression. While there is no single intervention for burnout, there are validated interventions (which are amenable to virtual reality (VR)) for anxiety and depression. UMassMemorial data from the Professional Well-Being Academic Consortium show that MD burnout and distress has increased since 2020. The investigators believe providing clinicians with a unique tool (VR) will be a feasible and efficacious way to tackle distress. It is known that only 1% of our MDs have done mindfulness training but nearly 50% are interested in doing so. Therefore, a self-administrable, interactive mindfulness program delivered over VR has great potential to reach clinicians who want to practice a more active form of mindfulness at a time convenient to them. The results of the study will provide preliminary evidence to determine if a take-home VR mindfulness program decreases clinician stress.

Read the detailed description

Cohorts 1 will be the intervention group Cohorts 2 will be the controls. Study endpoints include results from the following questionnaires:

  1. PROMIS - Short Form Anxiety (8 questions)
  2. PROMIS - Short Form Depression (8 questions)
  3. Perceived Stress Scale (10 questions)
  4. Connor-Davidson Brief Resilience Scale (10 questions)
  5. System Usability Scale (10 questions)

The intervention is a 12-week mindfulness-based VR intervention.

Cohort 1 will complete the questionnaires 1-4 at baseline (just before the intervention). They will be sent twice weekly reminders to use the VR for the duration of the 12-week intervention. After 12 weeks Cohort 1 will retake questionnaires 1-4 and take questionnaire 5, while Cohort 2 will then take questionnaires 1-4 and be provided the VR headsets. After another 12 weeks, Cohort 1 will take questionnaires 1-4 and be done with the study, while Cohort 2 will take questionnaires 1-5. After 12 more weeks, Cohort 2 will take questionnaires 1-4 and be done with the study.

02

Conditions studied

  • Wellness, Psychological
03

In context

Psychological Well-Being

971 studies on the registry are indexed under Psychological Well-Being; 502 are open to participants now.

This study's planned enrollment of 32 is below the median of 116 across 830 interventional studies indexed under Psychological Well-Being.

Browse Psychological Well-Being studies →

Lead sponsor

University of Massachusetts, Worcester is the lead sponsor of 288 studies on the registry; 54 are open to participants now.

Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • physician or APP employed by the Medical Group

Exclusion criteria

Exclusion Criteria:

  • Not willing to receive 2 texts per week
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Intervention - VR Mindfulness

    The intervention group will be given the VR headset for their unrestricted use over the 12 week intervention period. The VR headset is exceptionally easy and intuitive to use. Each participant will have the choice of 20 "locations" in which to use the mindfulness-based program. Each of the 20 locations/programs are different. They range in length from 5 minutes (introductory) to 20 minutes.

    Behavioral: VR mindfulness

  • No intervention
    Control

    The control arm will not have any intervention. However, at the conclusion of the study, all participants from the Control group will be given the VR intervention

Interventions

  • BehavioralVR mindfulness

    VR-based mindfulness

06

What researchers measure

Primary outcomes

  1. PROMIS - anxiety

    PROMIS Short Form - anxiety scale. Scores of 8-40; Higher is a worse outcome.

    Time frame: at baseline, after 12 weeks, then after another 12 weeks. We will compare results of the intervention group at 12 and 24 weeks to their baseline.

  2. PROMIS - anxiety

    PROMIS Short Form - anxiety scale. Scores of 8-40; Higher is a worse outcome.

    Time frame: at baseline, after 12 weeks, then after another 12 weeks. We will compare results of the control group at 12 and 24 weeks to their baseline.

  3. PROMIS - Depression

    PROMIS Short Form - Depression scale. Scores of 8-40; Higher is a worse outcome.

    Time frame: at baseline, after 12 weeks, then after another 12 weeks. We will compare results of the intervention group at 12 and 24 weeks to their baseline.

  4. PROMIS - Depression

    PROMIS Short Form - Depression scale. Scores of 8-40; Higher is a worse outcome.

    Time frame: at baseline, after 12 weeks, then after another 12 weeks. We will compare results of the control group at 12 and 24 weeks to their baseline.

  5. Resiliency

    Connor-Davidson Resiliency Scale. Scores of 0-40; Higher score is better.

    Time frame: at baseline, after 12 weeks, then after another 12 weeks. We will compare results of the intervention group at 12 and 24 weeks to their baseline.

  6. Resiliency

    Connor-Davidson Resiliency Scale. Scores of 0-40; Higher score is better.

    Time frame: at baseline, after 12 weeks, then after another 12 weeks. We will compare results of the control group at 12 and 24 weeks to their baseline.

  7. Stress scale

    Perceived Stress Score. Scores of 0-40; Higher score is worse.

    Time frame: at baseline, after 12 weeks, then after another 12 weeks. We will compare results of the intervention group at 12 and 24 weeks to their baseline.

  8. Stress scale

    Perceived Stress Score. Scores of 0-40; Higher score is worse.

    Time frame: at baseline, after 12 weeks, then after another 12 weeks. We will compare results of the control group at 12 and 24 weeks to their baseline.

  9. Usability

    Usability scale. Scores of 10-50; Higher score is better.

    Time frame: after 12 weeks we will dertermine the usability of the VR intervention in the intervention group

07

Study locations

1 site
  • UMassMemorial Health Care
    Worcester, Massachusetts 01655-0002, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06246539
Lead sponsor
University of Massachusetts, Worcester
Responsible party
Steven Bird (Professor of Emergency Medicine, University of Massachusetts, Worcester) — Principal investigator
First posted
Feb 7, 2024
Start date
Sep 1, 2026 (estimated)
Primary completion
Oct 1, 2027 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Aug 17, 2026

Study contacts

Steven Bird, MD
Contact
steven.bird@umassmemorial.org
508-421-1422
Steven Bird, MD
principal investigator · University of Massachusetts, Worcester

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion